At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 768 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 4, Multi-center Study of VESIcare® (Solifenacin Succinate) in Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life VIBRANT: VESIcare® Investigation of BotheR And Quality of Life iN subjecTs With OAB
In Brief
A Phase 4 clinical trial evaluating Placebo and Solifenacin Succinate for Urinary Bladder, Overactive. Completed, enrolled 768 participants across 59 sites.
Detailed Summary
Evaluate the effect of VESIcare® on symptom bother for subjects with OAB
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Bladder, Overactive
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedDec 2007
Primary CompletionJul 2008
TodayJul 2026
First PostedDec 14, 2007
Enrollment StartAug 1, 2007
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 18.6 years ago
Interventions
Placebodrug
Oral Administration
Solifenacin Succinatedrug
Oral Administration